To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
Both departments will be equipped with specialized professionals and state-of-the-art facilities ensuring the highest standards of care
Strong topline growth driven by solid performance across key brands.
More emphasis should be given on investing healthcare resources towards prevention of diseases rather than only focusing on diagnostic and therapeutic options
The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform
GSK and Flagship to jointly fund up to $150 million upfront
Campaign launched to spread awareness regarding dengue prevention and control
Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
Kwality Pharma already has registration of 20 molecules from the units and 20 are under registration
Subscribe To Our Newsletter & Stay Updated
